Allergan BIOCELL Breast Implant Recall Lawsuit

Note: This content is provided for informational purposes only. Douglas & London is no longer accepting cases related to Allergan BIOCELL Breast Implant-related injuries.

Allergan Breast Implant Recall History

On July 24, 2019, Allergan announced a recall of certain BIOCELL textured breast implants after reports showed a possible link between the implants and a type of non-Hodgkin’s lymphoma.

In December 2018, sales of textured Allergan breast implants were suspended in all 33 countries in Europe as well as Israel, Brazil, and Australia. Canada suspended Allergan’s license for its BIOCELL breast implants in May 2019 after an internal safety review concluded that these implants were linked to an increased risk of cancer. Before the recall, there was enough evidence to halt sales of Allergan’s BIOCELL breast implants in many countries across the world.

Allergan BIOCELL Breast Implants Linked to Cancer

Reports have shown that people with Allergan’s BIOCELL textured products were six times more likely to develop breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) than people with textured implants from other manufacturers.

The World Health Organization officially designated BIA-ALCL as a form of T-cell lymphoma that can develop following breast implantation.

NOTE: Douglas & London is a law firm and cannot provide medical advice. If you have medically related questions or concerns regarding any side effects that you may be experiencing or a recall notice you may have received, please contact your surgeon for more information.